Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
RPTX Stock Chart & Stats
$2.17
-$0.07(-5.15%)
At close: 4:00 PM EST
$2.17
-$0.07(-5.15%)
Day’s Range― - ―
52-Week Range$0.89 - $4.07
Previous CloseN/A
Volume283.97K
Average Volume (3M)138.92K
Market Cap
$76.47M
Enterprise Value-$49.16M
Total Cash (Recent Filing)$112.60M
Total Debt (Recent Filing)$342.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 03, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding42,959,170
10 Day Avg. Volume221,679
30 Day Avg. Volume138,921
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.37
Price to Sales (P/S)1.04
P/FCF Ratio-0.73
Enterprise Value/Market Cap-0.64
Enterprise Value/Revenue-4.14
Enterprise Value/Gross Profit-4.81
Enterprise Value/Ebitda0.68
Forecast
1Y Price Target
$3.00Price Target Upside38.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AcquisitionRepare Therapeutics to be acquired by XenoTherapeutics at a 10% premium to previous closing price.
Bears Say
Acquisition DetailsShareholders will receive cash per common share based on Repare's cash balance at the time of closing, less transaction fees and outstanding liabilities.
Clinical Data ConcernsInitial RP-1664 data raises questions over its viability, leading to a lower price target.
Drug Candidate ViabilityGiven the low objective response rate and the agent's toxicity profile, its potential as a successful drug candidate is questioned.
Repare Therapeutics News
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $0.89 and its highest was $4.07 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Repare Therapeutics Inc’s market cap is $76.47M.
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is Mar 03, 2026 which is in 88 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.233 by $0.313.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is -0.3.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,959,170 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.233. Following the earnings report the stock price went up 32.121%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Currently, no hedge funds are holding shares in RPTX
Repare Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (38.25% Upside)
$3.00 (38.25% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.37%
12-Months-Change
Fundamentals
Return on Equity
-49.78%
Trailing 12-Months
Asset Growth
-44.55%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
RPTX Stock 12 Month Forecast
Average Price Target
$3.00
▲(38.25% Upside)
Technical Analysis
Pliant Therapeutics
―
Lantern Pharma
―
Generation Bio
―
Prelude Therapeutics
―
Unicycive Therapeutics
―
Ownership Overview
1.45% Insiders
<0.01% Mutual Funds
56.71% Other Institutional Investors
41.83% Public Companies and
Individual Investors